{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:31:00Z","timestamp":1793035860893,"version":"4.5.0"},"reference-count":49,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1523,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1600-0560.2011.01762.x","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T10:16:58Z","timestamp":1311934618000},"page":"no-no","source":"Crossref","is-referenced-by-count":12,"title":["Expression of TWEAK in normal human skin, dermatitis and epidermal neoplasms: association with proliferation and differentiation of keratinocytes"],"prefix":"10.1111","author":[{"given":"Sandra","family":"Peternel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teo","family":"Manestar-Bla\u017ei\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Brajac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Prpi\u0107-Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Ka\u0161telan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,29]]},"reference":[{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"745.","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword.","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1403.","DOI":"10.1016\/S0006-2952(03)00490-8","article-title":"Regulation of proliferation, survival and apoptosis by members of the TNF superfamily.","volume":"66","author":"Gaur","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"32401.","DOI":"10.1074\/jbc.272.51.32401","article-title":"TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis.","volume":"272","author":"Chicheportiche","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"411.","DOI":"10.1038\/nrd2488","article-title":"The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting.","volume":"7","author":"Winkles","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"2330.","DOI":"10.1172\/JCI23486","article-title":"TWEAK induces liver progenitor cell proliferation.","volume":"115","author":"Jakubowski","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"76.","DOI":"10.1111\/j.1601-0825.2008.01474.x","article-title":"Transient TWEAK overexpression leads to a general salivary epithelial cell proliferation.","volume":"15","author":"Sugito","year":"2009","journal-title":"Oral Dis"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"116.","DOI":"10.1016\/S0165-5728(02)00368-5","article-title":"TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity.","volume":"133","author":"Desplat-J\u00e9go","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"24.","DOI":"10.1016\/j.cyto.2008.12.001","article-title":"TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells.","volume":"46","author":"Gao","year":"2009","journal-title":"Cytokine"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"681.","DOI":"10.1093\/cvr\/cvp360","article-title":"TWEAK is a positive regulator of cardiomyocyte proliferation.","volume":"85","author":"Novoyatleva","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"5826.","DOI":"10.1038\/sj.emboj.7601441","article-title":"TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration.","volume":"25","author":"Girgenrath","year":"2006","journal-title":"EMBO J"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1.","DOI":"10.1016\/j.cyto.2007.09.007","article-title":"TWEAKing tissue remodelling by a multifunctional cytokine: role of TWEAK\/Fn14 pathway in health and disease.","volume":"40","author":"Burkly","year":"2007","journal-title":"Cytokine"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"8455.","DOI":"10.1074\/jbc.274.13.8455","article-title":"TWEAK induces angiogenesis and proliferation of endothelial cells.","volume":"274","author":"Lynch","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"594.","DOI":"10.1161\/01.ATV.0000062883.93715.37","article-title":"TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity.","volume":"23","author":"Donohue","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"126.","DOI":"10.1186\/ar388","article-title":"Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies.","volume":"4","author":"Chicheportiche","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1175.","DOI":"10.1111\/j.0022-202X.2004.22419.x","article-title":"Induction of RANTES by TWEAK\/Fn14 interaction in human keratinocytes.","volume":"122","author":"Jin","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"540.","DOI":"10.1111\/j.1365-2249.2006.03233.x","article-title":"Proinflammatory effects of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts.","volume":"146","author":"Hosokawa","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"69.","DOI":"10.1016\/j.bbrc.2008.05.079","article-title":"Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells.","volume":"372","author":"Kang","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2610.","DOI":"10.4049\/jimmunol.177.4.2610","article-title":"TWEAK is a novel arthritogenic mediator.","volume":"177","author":"Perper","year":"2006","journal-title":"J Immunol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"173.","DOI":"10.1080\/03009740801898608","article-title":"Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.","volume":"37","author":"Park","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11033-010-0144-9","article-title":"TWEAK as a target for therapy in systemic lupus erythematosus.","volume":"38","author":"Leng","year":"2011","journal-title":"Mol Biol Rep"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"251.","DOI":"10.1016\/j.cytogfr.2009.05.002","article-title":"Considering TWEAK as a target for therapy in renal and vascular injury.","volume":"20","author":"Ortiz","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1842.","DOI":"10.1038\/sj.cdd.4402027","article-title":"TWEAK shall inherit the earth.","volume":"13","author":"Vince","year":"2006","journal-title":"Cell Death Differ"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"145.","DOI":"10.1007\/400_2008_18","article-title":"Therapeutic targeting of TWEAK\/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway.","volume":"49","author":"Michaelson","year":"2009","journal-title":"Results Probl Cell Differ"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"442.","DOI":"10.1093\/rheumatology\/ken006","article-title":"Involvement of TWEAK\/Fn14 interaction in the synovial inflammation of RA.","volume":"47","author":"Kamijo","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"5373.","DOI":"10.1210\/en.2009-0488","article-title":"Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes.","volume":"150","author":"Tiller","year":"2009","journal-title":"Endocrinology"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1434.","DOI":"10.1359\/jbmr.090305","article-title":"Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts.","volume":"24","author":"Vincent","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"10327.","DOI":"10.1074\/jbc.M511131200","article-title":"Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein.","volume":"281","author":"Dogra","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"3535.","DOI":"10.1002\/jnr.21443","article-title":"Age-dependent effects of TWEAK\/Fn14 receptor activation on neural progenitor cells.","volume":"85","author":"Hamill","year":"2007","journal-title":"J Neurosci Res"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"32317.","DOI":"10.1074\/jbc.M302518200","article-title":"TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14\/TweakR. Evidence for a second TWEAK receptor.","volume":"278","author":"Polek","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"267.","DOI":"10.1242\/jcs.115.2.267","article-title":"Dual role for TWEAK in angiogenic regulation.","volume":"115","author":"Jakubowski","year":"2002","journal-title":"J Cell Sci"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2613.","DOI":"10.1038\/sj.onc.1208208","article-title":"Tweak induces mammary epithelial branching morphogenesis.","volume":"24","author":"Michaelson","year":"2005","journal-title":"Oncogene"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"R143.","DOI":"10.1186\/ar2816","article-title":"Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.","volume":"11","author":"Schwartz","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"200.","DOI":"10.1016\/j.jaci.2010.11.005","article-title":"TNF-like weak inducer of apoptosis (TWEAK) and TNF-\u03b1 cooperate in the induction of keratinocyte apoptosis.","volume":"127","author":"Zimmermann","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"916.","DOI":"10.1161\/01.ATV.0000258972.10109.ff","article-title":"Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis.","volume":"27","author":"Blanco-Colio","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"440.","DOI":"10.1016\/j.atherosclerosis.2007.10.022","article-title":"Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease.","volume":"199","author":"Kralisch","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"465.","DOI":"10.2478\/v10042-009-0103-2","article-title":"Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis.","volume":"47","author":"Bielecki","year":"2009","journal-title":"Folia Histochem Cytobiol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"162.","DOI":"10.1006\/bbrc.2000.3913","article-title":"Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies.","volume":"279","author":"Chicheportiche","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1032.","DOI":"10.1016\/0190-9622(91)70303-J","article-title":"Immunohistochemical detection of proliferation and differentiation in discoid lupus erythematosus.","volume":"25","author":"de Jong","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"72.","DOI":"10.1111\/j.1365-2133.2005.06538.x","article-title":"Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation.","volume":"153","author":"Bovenschen","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"205.","DOI":"10.1016\/S0304-3835(01)00757-1","article-title":"Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16(INK4a) tumor suppressor.","volume":"176","author":"Mortier","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"145.","DOI":"10.1016\/j.canlet.2008.01.042","article-title":"Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.","volume":"264","author":"Kanellou","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"291.","DOI":"10.1111\/j.1365-2133.2007.08360.x","article-title":"Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers.","volume":"158","author":"Pacifico","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"59.","DOI":"10.1046\/j.0022-202x.2001.01380.x","article-title":"Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation.","volume":"117","author":"Bachmann","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"116.","DOI":"10.1097\/01.dad.0000154401.45465.ee","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer.","volume":"27","author":"St\u00e4nder","year":"2005","journal-title":"Am J Dermatopathol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1975.","DOI":"10.1016\/S0002-9440(10)64836-5","article-title":"Loss of Fas-ligand expression in mouse keratinocytes during UV carcinogenesis.","volume":"157","author":"Ouhtit","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB46|cit46","doi-asserted-by":"crossref","DOI":"10.1007\/s00403-011-1125-0","article-title":"Increased expression of TRAIL and its death receptors DR4 and DR5 in plaque psoriasis.","author":"Peternel","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"170.","DOI":"10.2353\/ajpath.2006.041354","article-title":"Fas pulls the trigger on psoriasis.","volume":"168","author":"Gilhar","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"746.","DOI":"10.1111\/j.0022-202X.2005.23878.x","article-title":"Increased expression and a potential anti-inflammatory role of TRAIL in atopic dermatitis.","volume":"125","author":"Vassina","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1600-0560.2011.01762.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"2438.","DOI":"10.1038\/sj.jid.5700477","article-title":"Fas ligand elicits a caspase-independent proinflammatory response in human keratinocytes: implications for dermatitis.","volume":"126","author":"Farley","year":"2006","journal-title":"J Invest Dermatol"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0560.2011.01762.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0560.2011.01762.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T04:03:36Z","timestamp":1638158616000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0560.2011.01762.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":49,"URL":"https:\/\/doi.org\/10.1111\/j.1600-0560.2011.01762.x","relation":{},"ISSN":["0303-6987"],"issn-type":[{"value":"0303-6987","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}